Ecovia Bio today announced the closing of a Series B funding round led by Pointe Angels, an independent angel investor group based in the Grosse Pointe communities east of Detroit, Michigan. The funding will support significant expansion of manufacturing capacity at Ecovia Bio's state-of-the-art Livonia facility to meet surging global demand for its AzuraBase and AzuraGel families of gamma polyglutamic acid (γ-PGA) and specialty biopolymer products across cosmetics, personal care, agriculture, and hygiene applications.

Ecovia Bio is a Michigan-based biotechnology company, a spinout from the University of Michigan, focused on the development and commercialization of sustainable, high-performance biopolymers derived from fermentation processes. The company's lead technology is based on gamma polyglutamic acid (γ-PGA), a natural biodegradable polymer with applications across multiple industries.